| Name | Title | Contact Details |
|---|
In 2016, OmniGuide Surgical and Domain Surgical were merged, creating an organization focused on providing better outcomes and a safer, more seamless surgical experience. Today, OmniGuide Surgical`s Enhanced Safety Flexible CO2 Laser Fibers and Domain Surgical`s FMX Ferromagnetic Technology are used in the most challenging surgical procedures throughout the world, safely delivering energy resulting in the preservation of healthy tissue. OmniGuide Surgical, based in Lexington, MA, USA, is the leader in flexible fiber CO2 laser technology; providing products that enhance surgical accuracy, access, and control for minimally invasive surgery, laparoscopy, and robotic-assisted surgery. Domain Surgical, located in Salt Lake City, UT, USA, provides a patented ferromagnetic technology designed to provide safety and predictability in select surgical procedures that require cutting, coagulating and sealing tissue.
Discovery Institute of Medical Education is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
careMESH is a first-of-its-kind healthcare communications platform bringing together a national provider directory, admit/discharge notifications, secure communications, and transition of care workflows into a single service. careMESH connects the care continuum by allowing any provider working with any electronic health record to communicate and collaborate with any other, instantly. careMESH`s cloud-based services efficiently allow hospitals and health systems, health information exchanges, public health agencies, and physician groups to communicate about patients, maintain complete control over when and where information is shared, and rapidly reduce reliance on outdated tools such as fax and phone calls.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
James Graham Brown Foundation is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.